<DOC>
	<DOCNO>NCT00875485</DOCNO>
	<brief_summary>This study evaluate immune response Hepatitis-A ( HAV ) Hepatitis B surface ( HBs ) antigen healthy subject age 12 15 year ( time primary vaccination ) , receive vaccination course GSK Biologicals ' Twinrix Adult Twinrix Junior vaccine , approximately 10 year ago primary study . The subject invite blood sample 11 , 12 , 13 , 14 15 year primary vaccination evaluate persistence immune response . For subject detect decreased immunity , presence immune memory hepatitis A &amp; B antigens investigated administration challenge dose appropriate vaccine 6 12 month Year 15 follow-up time-point . No new subject recruit booster phase study .</brief_summary>
	<brief_title>Evaluation Antibody Persistence &amp; Immune Memory Subjects Vaccinated During Adolescence With Twinrixâ„¢</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female receive complete primary vaccination course accord his/her group allocation primary study Written inform consent obtain subject . All subject must satisfy follow criterion entry challenge dose phase : A male female receive complete primary vaccination course accord his/her group allocation primary study . Subjects participate longterm followup phase primary study antibody concentration specify value antiHAV antibody and/ antiHBs antibody last available followup timepoints . Subjects investigator believe comply requirement protocol enrol study . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter challenge dose phase study . If subject female , must nonchildbearing potential , i.e . either surgically sterilize ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month vaccination . The following criterion check followup visit . If apply study entry , subject must include longterm followup visit . Use investigational nonregistered product ( drug vaccine ) since last blood sample visit . Administration hepatitis A , hepatitis B hepatitis combination vaccine since primary vaccination course primary study . History hepatitis A hepatitis B infection . Administration hepatitis A hepatitis B immunoglobulins and/or blood product within 3 month prior blood sampling . The following criterion check challenge dose phase . If apply , subject must include challenge dose phase : Use investigational nonregistered product ( drug vaccine ) within 30 day administration challenge dose plan use study period outside context study . Administration hepatitis A , hepatitis B hepatitis combination vaccine primary vaccination course primary study challenge dose visit . History hepatitis A hepatitis B infection . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior challenge dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine . Acute disease time . Administration immunoglobulins and/or blood product within three month precede administration challenge dose plan administration final blood sample point ( one month challenge dose ) . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Monovalent Hepatitis A</keyword>
	<keyword>hepatitis B vaccine</keyword>
	<keyword>Belgium Czech Republic</keyword>
</DOC>